Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis - Slideshow (NASDAQ:SYRE) 2026-04-14
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre Therapeutics s'envole grâce à des données positives sur le médicament contre la colite ulcéreuse | Benzinga France